Ovarian Cancer

Study Suggests Paclitaxel Is Cost-Effective in Treatment

Published in Cancer Weekly, May 8th, 1995

The following was released by Bristol-Myers Squibb Pharmaceutical Group:

A new study conducted by researchers at Toronto-Sunnybrook Regional Cancer Center suggests that the anti-cancer drug paclitaxel (Taxol), when combined with another agent (cisplatin), is a cost-effective addition to current therapies used to treat advanced ovarian cancer. The cost-effectiveness of treatment with paclitaxel/cisplatin in advanced ovarian cancer (AOC) compares favorably to many other widely accepted treatment strategies for diseases such as breast cancer, heart disease, diabetes and AIDS.

The study was presented by Allan Covens, M.D., Division of Gynecologic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry